Arrowhead Pharmaceuticals Reports Revenue Increase but Continued Net Losses in Q3 Fiscal 2026

Arrowhead Pharmaceuticals, Inc. reported its financial results for the third quarter of fiscal 2026, revealing a significant increase in revenue but continued net losses. For the three months ended June 30, 2026, the company generated $75.3 million in revenue, a substantial increase from $27.8 million in the same period last year. However, for the nine months ended June 30, 2026, total revenue decreased to $413.0 million from $573.0 million in the prior year. The operating loss for the quarter was $170.1 million, slightly higher than the $165.6 million loss reported in the same quarter of 2025. The net loss attributable to Arrowhead was $194.3 million, compared to a loss of $175.2 million in the prior year.

The company’s financial position showed notable changes, with total assets increasing to $2.1 billion as of June 30, 2026, up from $1.4 billion at the end of the previous fiscal year. This growth was primarily driven by a significant rise in available-for-sale securities, which increased to $1.5 billion from $692.8 million. Cash and cash equivalents, however, decreased to $54.8 million from $226.5 million, reflecting the company's ongoing investments in research and development and operational expenses. Arrowhead's total liabilities also rose sharply, reaching $1.6 billion, largely due to the issuance of convertible notes and increased deferred revenue.

Strategically, Arrowhead has made several key developments, including the launch of its FDA-approved product REDEMPLO® (plozasiran) for treating familial chylomicronemia syndrome. The company also entered into a licensing agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, which includes a $25 million upfront payment and potential milestone payments totaling up to $975 million. Additionally, Arrowhead has expanded its collaboration with Novartis, receiving a $200 million upfront payment as part of their agreement.

Operationally, Arrowhead has seen an increase in research and development expenses, which totaled $198.2 million for the quarter, up from $162.4 million in the prior year. This increase reflects the company's commitment to advancing its pipeline of RNA interference therapeutics. The company’s employee headcount has also grown, contributing to higher salary expenses, which increased by 77% in the latest quarter. Arrowhead continues to focus on expanding its clinical trials and product offerings, with several investigational therapies in various stages of development.

Looking ahead, Arrowhead Pharmaceuticals anticipates continued investment in its research and development efforts, particularly as it prepares for the commercialization of its products. The company expects to maintain sufficient liquidity to fund its operations through at least the next twelve months, supported by its cash reserves and ongoing collaborations. However, the company also acknowledges the inherent risks and uncertainties in the biotechnology sector, which may impact its future financial performance and operational outcomes.